Research and Markets: Analytical Tool: Anticancer VEGF/VEGFR Blockers.DUBLIN, Ireland -- VEGF VEGF vascular endothelial growth factor. is the best-studied angiogenesis factor angiogenesis factor n. A substance of 2000 to 20,000 molecular weight secreted by macrophages and stimulating neovascularization in healing wounds or in the stroma of tumors. and several published studies have shown that anti-angiogenic agents act synergistically syn·er·gis·tic adj. 1. Of or relating to synergy: a synergistic effect. 2. Producing or capable of producing synergy: synergistic drugs. 3. with chemotherapy or radiation therapy Research and Markets (http://www.researchandmarkets.com) has announced the addition of Analytical Tool: Anticancer anticancer, n a medicine or substance used to treat cancer. VEGF/VEGFR Blockers to their offering. A big hurdle in anti-angiogenesis research is the ability of different tumors to upregulate the expression of a set of different pro-angiogenic factors. Treating these cancers with drugs targeting VEGF is therefore unlikely to be fully effective for all indications. At the same time, VEGF is the best-studied angiogenesis factor and several published studies have shown that anti-angiogenic agents act synergistically with chemotherapy or radiation therapy. Thus, combinations of chemotherapy with anti-VEGF drugs should be more effective. This tool provides an analytical tool (database and report) for in-depth analysis of this field. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. This tool provides an immense amount of information structured and analyzed to assist in analyzing the competitive landscape. Additionally, a CD-ROM CD-ROM: see compact disc. CD-ROM in full compact disc read-only memory Type of computer storage medium that is read optically (e.g., by a laser). searchable database Refers to databases on the Web that are searchable by typing in a query. The term is quite redundant because all databases are searchable. In fact, that is one of their major features. has been developed, which is highly updated to reflect the most recent advances to block the VEGF signaling pathway under development, in order to help perform an analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for specific purposes. A significant advantage with this CD-ROM searchable database is that it provides well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, this CD-ROM searchable database gives better overview and specific search capabilities. This product will assist in finding the right partners, optimizing licensing deals, wisely choosing which projects give the best competitive advantage, and assuring that decisions have been based on the most accurate, validated and precise facts available. " BSG BSG Battlestar Galactica BSG Broadband Stakeholder Group (UK) BSG British Society of Gastroenterology (London, UK) BSG Business Systems Group BSG Business Solutions Group BSG Basigin Analytical Tool: Anticancer VEGF/VEGFR Blockers" is based on three major parts - Analysis - Information structure - Databases Included in this advantageous package are several products already appreciated by many customers representing an immense value: - VEGF Trap (Regeneron) - A Deal Worth more than 500M USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ? - The Anticancer VEGF Blockers Database (several additional subjects to enhance competitive analysis, see below). This tool includes: -Information on more that 100 companies active in anticancer VEGF/VEGFR and antiangiogenesis. -Information on more than 200 clinical trials in anticancer VEGF/VEGFR antagonist antagonist /an·tag·o·nist/ (an-tag´o-nist) 1. a substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could and antiangiogenesis. -Advanced analysis of general and specific trends in the pipeline. Possibility of performing advanced searches suited to your individual needs -Taking these searches a step further by generating specific and relevant tables and graphs for optimized support in your decision-making process -1000 anticancer VEGF/VEGFR and antiangiogenesis related patents and applications Among the VEGF/VEGFR inhibitors one drug, Avastin, has reached the market, and three are in late phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA stage of development. Among the most prominent ones Avastin, Neovastat and Vatalanib can be found. Beside the pure VEGF/VEGFR inhibitors, there are also several well-positioned receptor tyrosine kinase Receptor tyrosine kinases (RTK)s are the high affinity cell surface receptors for many polypeptide growth factors, cytokines and hormones. Of the ninety unique tyrosine kinase genes idenitified in the human genome, 58 encode receptor tyrosine kinase proteins. inhibitor of interest. Many of which already is on the market, and numerous in early stage of development. For more information visit http://www.researchandmarkets.com/reports/c2906 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion